Yecuris Corporation Announces Unique FRG Humanized Mouse Model for DMPK and ADMET Applications
(Portland, OR., February 22, 2010) —Yecuris™ Corporation, an Oregon-based biotechnology company providing human primary cells and reagents to the Life Science industry, announced today that it will present its new FRG knock-out (KO) humanized mouse model to media and members during the 49th Annual Meeting & ToxExpo™ of the Society of Toxicology in Salt Lake City, Utah, March 7-11, 2010. Yecuris’s FRG KO mouse and human primary hepatocyte cells support drug development, infectious disease, and cancer biology applications. Yecuris chose the SOT Meeting to introduce the FRG mouse because of the organization’s stated objective to showcase toxicology’s novel discoveries and scientific achievements over the past year.
According to John Bial, Yecuris chief executive officer, “The SOT meeting affords Yecuris an opportunity to introduce the humanized mouse model as a novel test platform for drug discovery, development and testing.” He adds, “Traditional technologies that supply human hepatocytes for these purposes are unable to meet the market need for availability, quality, predictability, and reproducibility. These cells are frequently contaminated with end of life and/or chemotherapy drug regimens that adversely affect the outcome of toxicology, drug safety and risk assessment testing. The Yecuris FRG knock out mouse model addresses these problems.”
Yecuris’s founder and chief scientific officer, Markus Grompe, M.D., said, “The FRG mouse model truly has exceeded our scientific expectations. After engraftment of human hepatocytes, the FRG knock out model exhibits a range of normal human liver functions, including an abundance of human serum albumin, human lipoproteins, enzymes, transporters and bile acids. Cultured hepatocytes derived by this method display normal drug induction responses and maintain a fully mature, adult liver phenotype. We now routinely see human hepatocyte repopulation up to 95%, making this new model a strong platform for drug toxicology and safety testing.”
NOTE: Yecuris will not be exhibiting at the SOT Meeting, but will be available for daily meetings.
Media and Customer Inquiries:
Yecuris welcomes the opportunity to share its solutions with industry media and analysts, as well as with potential customers and partners.
For a personal meeting, please contact:
John Bial, CEO
Lisa Wilson, Senior Scientist